Evidence map›Paper›PMID 38238788›Full record

ArticleRespiratory research2024

A formula for predicting emphysema extent in combined idiopathic pulmonary fibrosis and emphysema.

Athol U Wells, Joseph Jacob, Nicola Sverzellati, Gary Cross, Joseph Barnett, Angelo De Lauretis, Katerina Antoniou, Derek Weycker, Mark Atwood, Klaus-Uwe Kirchgaessler and 1 more

2 registry-linked trialsOpen access · goldAbstract readValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiratory research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00047645 phase3completednot on this map

A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b in Patients With Idiopathic Pulmonary Fibrosis

TypeinterventionalSponsorInterMuneRan2000 to 2002Enrolled330ConditionsIdiopathic Pulmonary FibrosisArmsInterferon-gamma 1b
NCT00075998 phase3terminatednot on this map

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Interferon Gamma-1b in Patients With Idiopathic Pulmonary Fibrosis (The INSPIRE Trial)

TypeinterventionalSponsorInterMuneRan2003 to 2007Enrolled826ConditionsIdiopathic Pulmonary Fibrosis, Lung Disease, Pulmonary FibrosisArmsInterferon gamma-1b ("Actimmune")
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 9 institutions in 6 countries.

Athol U WellsRoyal Brompton Hospital, Sydney Street, London, SW3 6NP, UK. RBHILD@rbht.nhs.uk.
Joseph JacobDepartment of Respiratory Medicine, University College London, London, UK.
Nicola SverzellatiScienze Radiologiche, Department of Medicine and Surgery, University Hospital Parma, Parma, Italy.
Gary CrossRoyal Free Hospital, London, UK.
Joseph BarnettRoyal Free Hospital, London, UK.
Angelo De LauretisDepartment of Respiratory Medicine, University of Insubria, Ospedale di Circolo, Varese, Italy.
Katerina AntoniouInterstitial Lung Disease Unit, Department of Thoracic Medicine, School of Medicine, University of Crete, Heraklion, Greece.
Derek WeyckerPolicy Analysis Inc. (PAI), Brookline, MA, USA.
Mark AtwoodPolicy Analysis Inc. (PAI), Brookline, MA, USA.
Klaus-Uwe KirchgaesslerF. Hoffmann-La Roche, Ltd., Basel, Switzerland.
Vincent CottinNational Reference Center for Rare Pulmonary Diseases (OrphaLung), Louis Pradel Hospital, Hospices Civils de Lyon, ERN-LUNG, Lyon, France.
Policy Analysis (United States) · USUniversity College London · GBHospices Civils de Lyon · FRRoche (Switzerland) · CHRoyal Brompton Hospital · GBThe Royal Free Hospital · GBUniversity of Crete · GRUniversity of Insubria · ITUniversity of Parma · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNo single pulmonary function test captures the functional effect of emphysema in idiopathic pulmonary fibrosis (IPF). Without experienced radiologists, other methods are needed to determine emphysema extent. Here, we report the development and validation of a formula to predict emphysema extent in patients with IPF and emphysema.

methodsThe development cohort included 76 patients with combined IPF and emphysema at the Royal Brompton Hospital, London, United Kingdom. The formula was derived using stepwise regression to generate the weighted combination of pulmonary function data that fitted best with emphysema extent on high-resolution computed tomography. Test cohorts included patients from two clinical trials (n = 455 [n = 174 with emphysema]; NCT00047645, NCT00075998) and a real-world cohort from the Royal Brompton Hospital (n = 191 [n = 110 with emphysema]). The formula is only applicable for patients with IPF and concomitant emphysema and accordingly was not used to detect the presence or absence of emphysema.

resultsThe formula was: predicted emphysema extent = 12.67 + (0.92 x percent predicted forced vital capacity) - (0.65 x percent predicted forced expiratory volume in 1 second) - (0.52 x percent predicted carbon monoxide diffusing capacity). A significant relationship between the formula and observed emphysema extent was found in both cohorts (R

conclusionThe formula, designed for use in patients with IPF and emphysema, demonstrated enhanced ability to predict emphysema extent versus individual pulmonary function tests.

trial registrationNCT00047645; NCT00075998.

Indexed as

EmphysemaIdiopathic Pulmonary FibrosisPulmonary EmphysemaClinical Trials as TopicHumansLungRetrospective StudiesVital CapacityClinical trial cohortInterstitial lung diseasePulmonary function testRadiologyReal-world cohort

Identifiers

PMID38238788
PMCPMC10795205
OpenAlexW4390966111

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.